Inc280研究
WebFeb 11, 2024 · Capmatinib (INC280) is an investigational, oral, potent and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the Agreement, Incyte … WebJun 4, 2012 · Drug: INC280 Drug: Gefitinib. Phase 2. Detailed Description: The Phase Ib dose escalation part was aimed at the determination of the MTD/RP2D of capmatinib in …
Inc280研究
Did you know?
Web除了上述药物,全球范围内还有许多在研的c-MET抑制剂,其中研究进展较快的有诺华的capmatinib(INC280)等。 Capmatinib是小分子MET抑制剂,今年2月,美国FDA已接受capmatinib治疗携带 MET 基因外显子14跳跃突变的晚期NSCLC患者的新药上市申请,并授予其优先审评资格。 WebResults. As of 9-Aug-2024, 94 pts with METΔex14 mutated advanced NSCLC had ≥18 weeks of follow-up (or discontinued earlier) and were included in this analysis (Cohort 4: 69 of 69 …
WebMar 11, 2024 · 总之,本研究表明靶向 cMET 可以有效抑制胰腺癌中的肿瘤生长,即使在晚期肿瘤阶段也是如此。 特别是,通过 cMET 抑制剂卡马替尼( INC280 )抑制肿瘤细胞中的吉西他滨耐药性可能会改善目前用于治疗胰腺癌患者的抗肿瘤治疗策略。 http://www.changbaicao.cn/trialsdetail-id-12013.html
Web药物名称INC280. 研究目的评估INC280单药在既往一线或二线治疗过的EGFR野生型的cMET失调的晚期/转移性非小细胞肺癌成年患者中的抗肿瘤活性与安全性。. 入选标准. 1 … WebDec 3, 2024 · 近年来,MET抑制剂的研究层出不穷,其中沃利替尼、Tepotinib和Capmatinib(卡马替尼,又名INC280)是目前研究数据相对较多的3个药物。 卡马替尼作为一种口服的高选择性小分子MET抑制剂,于2024年5月6日被美国FDA批准上市。
WebBackground. Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of ...
Web薬剤:INC280 (capmatinib) フェーズ:第II相; 進捗状況:募集終了; 試験種別:企業治験(グローバル) 1又は2ラインの全身治療歴があるEGFR野生型の進行性/転移性非小細胞肺がん(NSCLC)成人患者を対象としたc-MET阻害剤INC280経口投与による多施設共同4コホート … shutdown the internethttp://www.chicopharm.cn/new_detail/id/159.html shutdown the service process safelyWebCapmatinib (INCB28060, INC280, NVP-INC280) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1. shut down these resultsWebFeb 9, 2024 · 长春inc280片ii期临床试验-在egfr突变和cmet扩增的晚期非小细胞肺癌中进行的inc280研究 长春无开展的INC280片II期临床试验信息,需要患者受试者,主要适应症为非小细胞肺癌 shut down the system propertieshttp://www.kangantu.org/tumour/84502.html the pacifier parent reviewWebJul 3, 2015 · The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important in ovarian cancer metastasis. Using in vitro and ex vivo models, we demonstrate that INC280 inhibits HGF-induced c-MET, and reduces downstream signalling. the pacifier parents guide imdbWebApr 29, 2024 · 该研究纳入了MET 14号外显子跳跃突变或MET扩增的晚期NSCLC患者,包括脑转移患者。 ... Capmatinib(INC280)是强力MET抑制剂,对MET的抑制能力远强于其 … the pacifier part 2 full movie